Article,

The startup bugs

.
Nat Biotech, 31 (4): 279--281 (Apr 5, 2013)
DOI: 10.1038/nbt.2544

Abstract

Burgeoning research on the human microbiome is facilitating the development of more mechanistically driven probiotics. Charles Schmidt investigates a smattering of probiotic- and microbiota-modifying therapeutic opportunities arising from commercial efforts.

Tags

Users

  • @karthikraman

Comments and Reviews